Abstracts Archive - Page 1618 of 2425 - ACR Meeting Abstracts

Abstract Number: 3015 • 2016 ACR/ARHP Annual Meeting
The Good, the Bad and the Ugly – Refractory Rheumatoid Arthritis in 2016
Manuel Unger¹, Farideh Alasti², Gabriela Supp², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ³Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is characterised by the presence of a progressively destructive joint inflammation. Even in times of modern therapeutics, a subgroup of patients…
Abstract Number: 3016 • 2016 ACR/ARHP Annual Meeting
Validity of a 2-Component Disease Activity Score for Accurate Assessment of Synovitis in Rheumatoid Arthritis
Elizabeth M.A. Hensor^1,2, Paul McKeigue³, Philip G. Conaghan^1,2, Maya H. Buch^1,2, Jennifer H. Barrett^2,4, Jackie L. Nam^1,2, Marco Colombo⁵, Athina Spiliopoulou^5,6, Felix Agakov⁶, Stephen Kelly⁷, Myles J. Lewis⁷, Costantino Pitzalis⁷, Paul Emery^1,2, Ann W. Morgan^1,2 and IACON Consortium & PEAC Consortium, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Medical School, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom, ⁴School of Medicine, University of Leeds, Leeds, United Kingdom, ⁵Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom, ⁶Pharmatics Limited, Edinburgh, Edinburgh, United Kingdom, ⁷Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
Background/Purpose: The original Disease Activity Score (DAS) was derived from clinicians’ therapeutic decisions1, which may have been influenced by patient-subjective factors such as general health…
Abstract Number: 3017 • 2016 ACR/ARHP Annual Meeting
Elevated Neutrophil Extracellular Trap Levels Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA Levels in the Sputum of Individuals at-Risk for Future Rheumatoid Arthritis
M. Kristen Demoruelle¹, Monica Purmalek², Heather Rothfuss³, Michael Weisman⁴, Lindsay Kelmenson¹, Michael Mahler⁵, Jill M. Norris⁶, Brian Cherrington³, Mariana Kaplan², V. Michael Holers¹ and Kevin D. Deane¹, ¹Rheumatology Division, University of Colorado Denver, Aurora, CO, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Zoology and Physiology, University of Wyoming, Laramie, WY, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Research and Development, Inova Diagnostics, San Diego, CA, ⁶Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: The initial site of anti-citrullinated protein antibody (ACPA) generation in RA has been proposed to be a mucosal site. We have previously demonstrated ACPA…
Abstract Number: 3018 • 2016 ACR/ARHP Annual Meeting
The Analysis of Severity of Arthritis in the Intestinal Microbiota-Humanized Mice
Yuichi Maeda¹, Masato Matsushita², Masashi Narazaki³, Yukihiko Saeki^4,5, Atsushi Kumanogoh⁶ and Kiyoshi Takeda⁷, ¹Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ²Rheumatology, Osaka Minami Medical Center, Osaka, Japan, ³Osaka University Graduate School of Medicine, Suita, Japan, ⁴Dept of Clinical research, Osaka-Minami Medical Ctr, Osaka, Japan, ⁵Dept of Clinical Research, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁶Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ⁷Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Although various genetic factors have been implicated in susceptibility to rheumatoid arthritis (RA), environmental factors including smoking, periodontal disease and hormones are also necessary…
Abstract Number: 3019 • 2016 ACR/ARHP Annual Meeting
Sputum Antibodies to Individual Citrullinated Protein/Peptide Antigens Are Elevated in Subjects at-Risk of Future RA and Subjects with Established Disease
Emily Bowers¹, M. Kristen Demoruelle², Michael Weisman³, Jill M. Norris⁴, William H. Robinson⁵, V. Michael Holers² and Kevin D. Deane², ¹Medicine, University of Colorado Denver, Aurora, CO, ²Rheumatology Division, University of Colorado Denver, Aurora, CO, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Stanford University School of Medicine, Stanford, CA
Background/Purpose: Multiple studies demonstrate that ACPAs are elevated in the serum years prior to the onset of seropositive RA during a preclinical period of autoimmunity.…
Abstract Number: 3020 • 2016 ACR/ARHP Annual Meeting
Citrullination of Inhibitor of DNA Binding-1 at Specific Locations Leads to Autoantigenicity in Rheumatoid Arthritis
Ray A. Ohara¹, Henriette A. Remmer², Phillip L. Campbell³, David A. Fox³ and Jeffrey H. Ruth³, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Inhibitor of DNA binding-1 (Id1) is a nuclear transcription factor that regulates cell growth and differentiation via selective binding and sequestering of other transcription…
Abstract Number: 3021 • 2016 ACR/ARHP Annual Meeting
Frequency of Arthralgia, Seropositivity, and Seropositive Arthralgia and Their Association with Development of Rheumatoid Arthritis in a Cohort of Indigenous North Americans with or without a First Degree Relative with Rheumatoid Arthritis
Elizabeth Ferucci¹, Carol Hitchon², Irene Smolik³, David Robinson³ and Hani El-Gabalawy⁴, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: Anti-citrullinated peptide antibodies and/or rheumatoid factor (RF) in the setting of arthralgia (“seropositive arthralgia”) has been associated with a high risk of development of…
Abstract Number: 3022 • 2016 ACR/ARHP Annual Meeting
Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis
Erika Darrah¹, Jon T. Giles², Ryan Davis¹, Pooja Naik¹, Maximilian Konig¹ and Felipe Andrade¹, ¹Department of Medicine, Division of Rheumatology, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ²Columbia University, College of Physicians and Surgeons, Division of Rheumatology, New York, NY
Background/Purpose: The mechanisms that drive clinical heterogeneity and outcomes in patients with rheumatoid arthritis (RA) are poorly understood, but precise biomarkers may identify clinically unique…
Abstract Number: 3023 • 2016 ACR/ARHP Annual Meeting
Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies
Iain B. McInnes¹, Joel Kremer², Paul Emery³, Steven H. Zuckerman⁴, Giacomo Ruotolo⁴, Chadi Saifan⁴, Lei Chen⁴, Shayami Thanabalasundrum⁴, Sarah Witt⁴ and William Macias⁴, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain, ²The Center for Rheumatology, Albany Medical College, Albany, NY, ³University of Leeds, Midlothian, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In patients with active RA an increase in lipid analytes has been observed after treatment with janus kinase inhibitors and other disease-modifying antirheumatic drugs.1…
Abstract Number: 3024 • 2016 ACR/ARHP Annual Meeting
Major Adverse Cardiovascular Events: Risk Factors in Patients with RA Treated with Tofacitinib
Christina Charles-Schoeman¹, Hernan Valdez², Koshika Soma², Lie-Ju Hwang², Ryan DeMasi², Mary Boy³ and Iain B McInnes⁴, ¹University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, New York, NY, ³Pfizer Inc, Groton, CT, ⁴Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: RA patients (pts) are at increased risk of myocardial infarction (MI) and stroke that cannot be completely explained by traditional cardiovascular (CV) risk factors.…
Abstract Number: 3025 • 2016 ACR/ARHP Annual Meeting
The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies
Mark C. Genovese¹, R Westhovens², Arthur Kavanaugh³, Luc Meuleners⁴, Annegret Van der Aa⁴, Pille Harrison⁴ and Chantal Tasset⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³University of California San Diego, La Jolla, CA, ⁴Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that showed rapid and sustained improvements of signs and symptoms of active rheumatoid…
Abstract Number: 3026 • 2016 ACR/ARHP Annual Meeting
The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study
Sheng-Xiao Zhang¹, Miao Miao², Xiao-Qing Liu², Xiao-Wen Ma², Xiao-Yan Wu² and Xiao-Feng Li¹, ¹Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ²The Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Current therapy for rheumatoid arthritis (RA) often leads to excessive immunosuppression induced by glucocorticoids and DMARDs. Low-dose Interleukin 2 (IL-2) has been showed to induce…
Abstract Number: 3027 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib
Kevin L. Winthrop¹, Stephen Lindsey², Michael Weinblatt³, Tsutomu Takeuchi⁴, David Hyslop⁵, Maher Issa⁵, Lei Chen⁵, John Bradley⁵, Christina Dickson⁵ and Roy Fleischmann⁶, ¹Oregon Health and Sciences University, Portland, OR, ²Ochsner Medical Center, Baton Rouge, LA, ³Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Compared to the general population, RA patients (pts) have an increased risk of herpes zoster (HZ) due to their disease and various DMARD therapies…
Abstract Number: 3028 • 2016 ACR/ARHP Annual Meeting
A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA
Danielle M. Gerlag^1,2, Mary Safy³, Karen I. Maijer⁴, Sander W. Tas⁵, Mirian Starmans-kool⁶, A. van Tubergen⁷, M. Janssen⁸ and Paul-Peter Tak⁹, ¹Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Current address: GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom, ³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Orbis Medical Center, Geleen-Sittard, Netherlands, ⁷Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁸Rheumatology Dept, Rijnstate Hospital, Arnhem, Netherlands, ⁹currently: , Ghent University, Ghent, Belgium, Ghent, Belgium
Background/Purpose: The development of clinical signs and symptoms of seropositive rheumatoid arthritis (RA) is often preceded by a phase of systemic autoimmunity. This offers a…
Abstract Number: 3029 • 2016 ACR/ARHP Annual Meeting
Ultrasonography of Major Salivary Glands in Patients Suspected with Primary Sjögren’s Syndrome: Comparison with Salivary Gland Biopsy and Classification Criteria
Esther Mossel¹, Konstantina Delli², Jolien F. van Nimwegen³, Alja J. Stel³, Erlin A. Haacke⁴, Fred K.L. Spijkervet⁵, Frans G.M. Kroese³, Arjan Vissink², Hendrika Bootsma⁶ and Suzanne Arends³, ¹University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands
Background/Purpose: Ultrasonography of major salivary glands (sUS) is applied in the diagnostic work-up of primary Sjögren's syndrome (pSS). This study aims to assess (i) the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].